z-logo
open-access-imgOpen Access
CXCR 4‐mediated osteosarcoma growth and pulmonary metastasis is suppressed by Micro RNA ‐613
Author(s) -
Zhu Yong,
Tang Lanhua,
Zhao Shushan,
Sun Buhua,
Cheng Liang,
Tang Yifu,
Luo Zhongwei,
Lin Zhangyuan,
Zhu Jianxi,
Zhu Weihong,
Zhao Ruibo,
Lu Bangbao,
Long Haitao
Publication year - 2018
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13653
Subject(s) - osteosarcoma , cancer research , stromal cell , metastasis , cell growth , transforming growth factor , biology , medicine , cancer , genetics
Osteosarcoma is the most common primary bone malignancy. Recently, studies showed chemokine receptor 4 ( CXCR 4) played a critical role in osteosarcoma. However, the regulation of CXCR 4 is not fully understood. micro RNA s are short, non‐coding RNA s that play an important roles in post‐transcriptional regulation of gene expression in a variety of diseases including osteosarcoma. miR‐613 is a newly discovered mi RNA and has been reported to function as a tumor suppressor in many cancers. In this study, we confirmed that both Stromal Cell‐Derived Factor ( SDF ‐1) and CXCR 4 could be prognostic markers for osteosarcoma. Meanwhile this study found that SDF ‐1/ CXCR 4 pathway regulated osteosarcoma cells proliferation, migration and reduced apoptosis. Besides, we demonstrated that miR‐613 was significantly downregulated in osteosarcoma patients. Elevated expression of miR‐613 directly suppressed CXCR 4 expression and then decreased the proliferation, migration and induced apoptosis of osteosarcoma cells. Moreover, our study found that CXCR 4 promoted the development of lung metastases and inhibition of CXCR 4 by miR‐613 reduced lung metastases. These data indicated that CXCR 4 mediated osteosarcoma cell growth and lung metastases and this effect can be suppressed by miR‐613 through directly downregulating CXCR 4.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here